Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Munich Biotech: Catioms for cancer

Two of the major drawbacks of standard chemotherapy are severe side effects due to nonspecific drug actions at non-tumor sites and the development of multidrug resistance. Munich Biotech AG believes that targeting the new blood vessels surrounding tumors addresses both problems. The theory is that side effects can be minimized through delivery of chemotherapeutics using cationic liposomes, which selectively bind to neovascular cells

Read the full 630 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE